Pharmaxis tumbles on FDA rejection of Bronchitol in CF
This article was originally published in Scrip
Given the unanimous snub it got in January from a US FDA panel of advisers, it came as little surprise regulators rejected Pharmaxis' new drug application for Bronchitol, an experimental dry-powder mannitol medicine, as a treatment to improve pulmonary function in patients as young as 6 years with cystic fibrosis (CF).
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.